Angel Matthew
High convictionDirector, CEO and President, 10% Owner · Tempest Therapeutics, Inc.
Every open-market stock purchase Angel Matthew has reported to the SEC on Form 4 that met our signal bar, parsed straight from the filings. Insiders sell for many reasons, but they buy with their own money for one — this page tracks where how the prices paid compare to where the stock trades now.
Where the buys stand today
- TPST−51.2% vs price paidTempest Therapeutics, Inc.
2 purchases totalling $1.0M at an average of $2.16 per share; the stock last traded at $1.06. See all insider buying in TPST →
Avg price paid$2.16Latest price$1.06Market cap$15.8M
All reported buys
Get alerted the next time Angel Matthew — or any insider — buys
We watch every Form 4 as it hits SEC EDGAR and alert you when insiders cluster into the same stock.
About this data
Figures are parsed from Angel Matthew's Form 4 filings on SEC EDGAR (CIK 1931356) and cover open-market purchases (transaction code P) — grants, option exercises, and sales are excluded, which is why totals here can differ from raw filing counts. Every row links to its source document.
This page is informational and reflects public filing data. It is not investment advice.